A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MAR002 in Participants With Acromegaly (TROUGH-2)
Condition studied
Acromegaly
Investigational medicinal product(s)
Every trial of Cyanocobalamin, L-arginine and MAR002 across our registers →
Eligibility
Primary endpoint
TEAEs, SAEs, and other safety evaluations, including physical exam, vital signs, ECG, and safety laboratories through EOS, Percent change from baseline in serum IGF-1 levels as an average of Week 8 and Week 10
Endpoint detail
Improvement from baseline in acromegaly symptoms as measured by AcroQoL and ASD at Week 10, Improvement from baseline in acromegaly symptoms by Investigator assessment, Change from baseline in ring size
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View 2026-526340-12-00 on CTIS ↗ ← All trials in the EU